Committed to researching treatments for
peripheral artery disease, Medtronic, Inc. MDT today announced that
patient enrollment in a landmark study of its IN.PACT Amphirion drug-eluting
balloon is complete, with initial results expected in 2013.
The largest randomized controlled trial of its kind, IN.PACT DEEP is designed
to assess the safety and efficacy of the IN.PACT Amphirion drug-eluting
balloon as a treatment for one of the most severe forms of peripheral artery
disease -- critical limb ischemia that occurs below the knee.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in